Skip to main content

24.04.2024 | Original Article

Association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography

verfasst von: Azhi ShaMa, Chunmei Xu, Yingying Huang, Chunlan Ma, Jingyue Hu, Zhuxin Li, Chunyu Zeng

Erschienen in: Herz

Einloggen, um Zugang zu erhalten

Abstract

Objective

Many previous studies reported the relationship between lipoprotein(a) and cardiovascular disease, but the conclusions were controversial. The aim of our study was to retrospectively investigate the association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography.

Methods

We collected and compared clinical information of patients hospitalized for coronary angiography. Multivariable hierarchical logistic regression was used to evaluate the association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography.

Results

There were no significant differences in gender, hypertension, APOA1, smoking, hyperuricemia, obesity, acute myocardial infarction (AMI), cardiac insufficiency, family history of diabetes, or family history of hyperlipidemia among the four groups of lipoprotein(a). Elevated lipoprotein(a) does not increase the risk of hypertriglyceridemia, while elevated lipoprotein(a) increases the risk of high total cholesterol and high low-density lipoprotein cholesterol (LDL-c). Elevated lipoprotein(a) increases the risk of diabetes and premature coronary artery disease (CAD). Elevated lipoprotein(a) increases the incidence of CAD, multivessel lesions, and percutaneous coronary intervention (PCI). Multivariate logistic regression analysis further showed that elevated lipoprotein(a) increases the incidence of high total cholesterol, high LDL‑c, diabetes, CAD, premature CAD, multivessel lesions, and PCI.

Conclusion

The findings indicated that elevated lipoprotein(a) had no obvious relationship with hypertension and obesity. Elevated lipoprotein(a) increases the risk of high total cholesterol, high LDL‑c, and premature CAD, and increases the occurrence and severity of coronary heart disease.
Literatur
1.
Zurück zum Zitat Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S (2019) A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 234(10):16812–16823CrossRefPubMed Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S (2019) A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 234(10):16812–16823CrossRefPubMed
2.
Zurück zum Zitat Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Banach M (2020) What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? Prog Cardiovasc Dis 63(3):219–227CrossRefPubMed Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Banach M (2020) What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? Prog Cardiovasc Dis 63(3):219–227CrossRefPubMed
3.
Zurück zum Zitat Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, et al (2022) Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart 109(1):18–25CrossRefPubMed Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, et al (2022) Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart 109(1):18–25CrossRefPubMed
4.
Zurück zum Zitat Tsimikas S, Stroes ESG (2020) The dedicated “Lp(a) clinic”: A concept whose time has arrived? Atherosclerosis 300:1–9CrossRefPubMed Tsimikas S, Stroes ESG (2020) The dedicated “Lp(a) clinic”: A concept whose time has arrived? Atherosclerosis 300:1–9CrossRefPubMed
5.
Zurück zum Zitat Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925–3946CrossRefPubMedPubMedCentral Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43(39):3925–3946CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al (2012) Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 125(2):241–249CrossRefPubMed Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al (2012) Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 125(2):241–249CrossRefPubMed
7.
Zurück zum Zitat Kim J, Choi SW, Lee YS, Lee JM, Chung H, Woo JS, et al (2022) Correlations Between Coronary Artery Disease, Coronary Artery Calcium Score, and Lipoprotein(a) Level in Korea. Ther Clin Risk Manag 18:981–987CrossRefPubMedPubMedCentral Kim J, Choi SW, Lee YS, Lee JM, Chung H, Woo JS, et al (2022) Correlations Between Coronary Artery Disease, Coronary Artery Calcium Score, and Lipoprotein(a) Level in Korea. Ther Clin Risk Manag 18:981–987CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Langsted A, Nordestgaard BG (2021) Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. Curr Atheroscler Rep 23(8):46CrossRefPubMed Langsted A, Nordestgaard BG (2021) Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. Curr Atheroscler Rep 23(8):46CrossRefPubMed
9.
Zurück zum Zitat Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al (2023) Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules 28(3):969CrossRefPubMedPubMedCentral Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al (2023) Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules 28(3):969CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Jang AY, Han SH, Sohn IS, Oh PC, Koh KK (2020) Lipoprotein(a) and Cardiovascular Diseases—Revisited. Circ J 84(6):867–874CrossRefPubMed Jang AY, Han SH, Sohn IS, Oh PC, Koh KK (2020) Lipoprotein(a) and Cardiovascular Diseases—Revisited. Circ J 84(6):867–874CrossRefPubMed
11.
Zurück zum Zitat de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, Zwinderman AH, et al (2022) Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol 29(5):779–792CrossRefPubMed de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, Zwinderman AH, et al (2022) Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol 29(5):779–792CrossRefPubMed
12.
Zurück zum Zitat Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, et al (2018) Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J 39:2577–2585CrossRefPubMed Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, et al (2018) Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J 39:2577–2585CrossRefPubMed
13.
Zurück zum Zitat Swerdlow DI, Rider DA, Yavari A, Wikström Lindholm M, Campion GV, Nissen SE (2022) Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res 118(5):1218–1231CrossRefPubMed Swerdlow DI, Rider DA, Yavari A, Wikström Lindholm M, Campion GV, Nissen SE (2022) Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res 118(5):1218–1231CrossRefPubMed
14.
Zurück zum Zitat O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al (2019) Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 139(12):1483–1492CrossRefPubMed O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al (2019) Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 139(12):1483–1492CrossRefPubMed
15.
Zurück zum Zitat Enkhmaa B, Anuurad E, Berglund L (2016) Lipoprotein (a): Impact by ethnicity and environmental and medical conditions. J Lipid Res 57(7):1111–25CrossRef Enkhmaa B, Anuurad E, Berglund L (2016) Lipoprotein (a): Impact by ethnicity and environmental and medical conditions. J Lipid Res 57(7):1111–25CrossRef
16.
Zurück zum Zitat Li JJ, Ma CS, Zhao D, Yan XW; Beijing Heart Society and Expert Committee (2022) Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement. JACC Asia 2(6):653–665. Li JJ, Ma CS, Zhao D, Yan XW; Beijing Heart Society and Expert Committee (2022) Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement. JACC Asia 2(6):653–665.
17.
Zurück zum Zitat Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG (2022) Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis 355:76–82CrossRefPubMed Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG (2022) Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis 355:76–82CrossRefPubMed
18.
Zurück zum Zitat Muhanhali D, Zhai T, Cai Z, Ling Y (2020) Lipoprotein(a) concentration is associated with risk of type 2 diabetes and cardiovascular events in a Chinese population with very high cardiovascular risk. Endocrine 69(1):63–72CrossRefPubMed Muhanhali D, Zhai T, Cai Z, Ling Y (2020) Lipoprotein(a) concentration is associated with risk of type 2 diabetes and cardiovascular events in a Chinese population with very high cardiovascular risk. Endocrine 69(1):63–72CrossRefPubMed
19.
Zurück zum Zitat Borghi C (2002) Interactions between hypercholesterolemia and hypertension: Implications for therapy. Curr Opin Nephrol Hypertens 5:489–496CrossRef Borghi C (2002) Interactions between hypercholesterolemia and hypertension: Implications for therapy. Curr Opin Nephrol Hypertens 5:489–496CrossRef
20.
Zurück zum Zitat Brosolo G, Da Porto A, Marcante S, Picci A, Capilupi F, Capilupi P, et al (2023) Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension? Int J Mol Sci 24(17):13363CrossRefPubMedPubMedCentral Brosolo G, Da Porto A, Marcante S, Picci A, Capilupi F, Capilupi P, et al (2023) Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension? Int J Mol Sci 24(17):13363CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S (1998) Lp(a) in hypertensive patients. J Hum Hypertens 12(2):83–89CrossRefPubMed Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S (1998) Lp(a) in hypertensive patients. J Hum Hypertens 12(2):83–89CrossRefPubMed
22.
Zurück zum Zitat Ward NC, Nolde JM, Chan J, Carnagarin R, Watts GF, Schlaich MP (2021) Lipoprotein (a) and Hypertension. Curr Hypertens Rep 23(12):44CrossRefPubMed Ward NC, Nolde JM, Chan J, Carnagarin R, Watts GF, Schlaich MP (2021) Lipoprotein (a) and Hypertension. Curr Hypertens Rep 23(12):44CrossRefPubMed
23.
Zurück zum Zitat Marcovina SM (2023) Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease. Crit Rev Clin Lab Sci 14:1–13 Marcovina SM (2023) Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease. Crit Rev Clin Lab Sci 14:1–13
24.
Zurück zum Zitat Raitakari O, Kartiosuo N, Pahkala K, Hutri-Kähönen N, Bazzano LA, Chen W, et al (2023) Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood. Circulation 147(1):23–31CrossRefPubMed Raitakari O, Kartiosuo N, Pahkala K, Hutri-Kähönen N, Bazzano LA, Chen W, et al (2023) Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood. Circulation 147(1):23–31CrossRefPubMed
25.
Zurück zum Zitat Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al (2019) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188CrossRef Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al (2019) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188CrossRef
26.
Zurück zum Zitat Usalp S, Altuntaş E, Bağırtan B, Karabay KÖ (2023) Comparison of serum lipoprotein(a) levels in young and middle-aged patients presenting for the first time with ST-elevation myocardial infarction: a single-centre study. Cardiovasc J Afr 25(34):1–5 Usalp S, Altuntaş E, Bağırtan B, Karabay KÖ (2023) Comparison of serum lipoprotein(a) levels in young and middle-aged patients presenting for the first time with ST-elevation myocardial infarction: a single-centre study. Cardiovasc J Afr 25(34):1–5
27.
Zurück zum Zitat Tada H, Yamagami K, Sakata K, Usui S, Kawashiri MA, Takamura M (2024) Healthy lifestyle, lipoprotein (a) levels and the risk of coronary artery disease. Eur J Clin Invest 54(1):e14093CrossRef Tada H, Yamagami K, Sakata K, Usui S, Kawashiri MA, Takamura M (2024) Healthy lifestyle, lipoprotein (a) levels and the risk of coronary artery disease. Eur J Clin Invest 54(1):e14093CrossRef
Metadaten
Titel
Association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography
verfasst von
Azhi ShaMa
Chunmei Xu
Yingying Huang
Chunlan Ma
Jingyue Hu
Zhuxin Li
Chunyu Zeng
Publikationsdatum
24.04.2024
Verlag
Springer Medizin
Erschienen in
Herz
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-024-05247-0

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.